Literature DB >> 2176543

Chromosomal breakpoints in cholangiocarcinoma cell lines.

P D Storto1, S L Saidman, A J Demetris, E Letessier, T L Whiteside, S M Gollin.   

Abstract

Little is known about the genetics and biology of cholangiocarcinoma (intrahepatic bile duct carcinoma). Only three human bile duct carcinoma cell lines have been described in the literature. We present the first detailed cytogenetic analysis of two cell lines; a new cell line designated PCI:SG231, established in our laboratory, and RPMI-7451, a previously established cell line. Both lines had highly aneuploid karyotypes with complex rearrangements including marker chromosomes. PCI:SG231, harvested after 50 days in culture, had a modal and median chromosome number of 65, and many cells contained double-minute chromosomes. RPMI-7451 had a modal and median chromosome number of 67. C-banding confirmed the presence of dicentric chromosomes in PCI:SG231. Q-banding confirmed the absence of the Y chromosome in PCI:SG231 and the presence of a der(1)t(Y;1)(q11;p11) chromosome in RPMI-7451. Numerical abnormalities common to both lines included trisomies 2, 5, 11, and 20. Chromosomes 1, 5, 7, and 12 were most commonly involved in structural abnormalities in both lines. Consistent chromosomal breakpoints included 7q22 and 12p11-12. PCI:SG231 was tumorigenic in immunosuppressed nude mice and was histologically similar to the original tumor. Additional cholangiocarcinoma cell lines are being developed to continue the study of the genetics and cell biology of this disorder.

Entities:  

Mesh:

Year:  1990        PMID: 2176543     DOI: 10.1002/gcc.2870020408

Source DB:  PubMed          Journal:  Genes Chromosomes Cancer        ISSN: 1045-2257            Impact factor:   5.006


  26 in total

1.  Neuropeptide Y inhibits cholangiocarcinoma cell growth and invasion.

Authors:  Sharon DeMorrow; Paolo Onori; Julie Venter; Pietro Invernizzi; Gabriel Frampton; Mellanie White; Antonio Franchitto; Shelley Kopriva; Francesca Bernuzzi; Heather Francis; Monique Coufal; Shannon Glaser; Giammarco Fava; Fanyin Meng; Domenico Alvaro; Guido Carpino; Eugenio Gaudio; Gianfranco Alpini
Journal:  Am J Physiol Cell Physiol       Date:  2011-01-26       Impact factor: 4.249

2.  miR-24 Inhibition Increases Menin Expression and Decreases Cholangiocarcinoma Proliferation.

Authors:  Laurent Ehrlich; Chad Hall; Julie Venter; David Dostal; Francesca Bernuzzi; Pietro Invernizzi; Fanyin Meng; Jerome P Trzeciakowski; Tianhao Zhou; Holly Standeford; Gianfranco Alpini; Terry C Lairmore; Shannon Glaser
Journal:  Am J Pathol       Date:  2017-01-11       Impact factor: 4.307

3.  Interleukin-6-driven progranulin expression increases cholangiocarcinoma growth by an Akt-dependent mechanism.

Authors:  Gabriel Frampton; Pietro Invernizzi; Francesca Bernuzzi; Hae Yong Pae; Matthew Quinn; Darijana Horvat; Cheryl Galindo; Li Huang; Matthew McMillin; Brandon Cooper; Lorenza Rimassa; Sharon DeMorrow
Journal:  Gut       Date:  2011-11-07       Impact factor: 23.059

4.  miR-34a-dependent overexpression of Per1 decreases cholangiocarcinoma growth.

Authors:  Yuyan Han; Fanyin Meng; Julie Venter; Nan Wu; Ying Wan; Holly Standeford; Heather Francis; Cynthia Meininger; John Greene; Jerome P Trzeciakowski; Laurent Ehrlich; Shannon Glaser; Gianfranco Alpini
Journal:  J Hepatol       Date:  2016-02-24       Impact factor: 25.083

5.  Inhibition of the apelin/apelin receptor axis decreases cholangiocarcinoma growth.

Authors:  Chad Hall; Laurent Ehrlich; Julie Venter; April O'Brien; Tori White; Tianhao Zhou; Tien Dang; Fanyin Meng; Pietro Invernizzi; Francesca Bernuzzi; Gianfranco Alpini; Terry C Lairmore; Shannon Glaser
Journal:  Cancer Lett       Date:  2016-11-26       Impact factor: 8.679

6.  Extracellular vesicles carry microRNA-195 to intrahepatic cholangiocarcinoma and improve survival in a rat model.

Authors:  Ling Li; Klaus Piontek; Masaharu Ishida; Michel Fausther; Jonathan A Dranoff; Rongdang Fu; Esteban Mezey; Stephen J Gould; Francis K Fordjour; Stephen J Meltzer; Alphonse E Sirica; Florin M Selaru
Journal:  Hepatology       Date:  2016-08-29       Impact factor: 17.425

7.  Establishment and characterization of a cholangiocarcinoma cell line (RMCCA-1) from a Thai patient.

Authors:  Panthip Rattanasinganchan; Kawin Leelawat; Sa-ard Treepongkaruna; Chintana Tocharoentanaphol; Somboon Subwongcharoen; Tuangporn Suthiphongchai; Rutaiwan Tohtong
Journal:  World J Gastroenterol       Date:  2006-10-28       Impact factor: 5.742

8.  Small proline-rich proteins (SPRR) function as SH3 domain ligands, increase resistance to injury and are associated with epithelial-mesenchymal transition (EMT) in cholangiocytes.

Authors:  Anthony J Demetris; Susan Specht; Isao Nozaki; John G Lunz; Donna Beer Stolz; Noriko Murase; Tong Wu
Journal:  J Hepatol       Date:  2007-12-17       Impact factor: 25.083

9.  Caffeic acid phenethyl ester decreases cholangiocarcinoma growth by inhibition of NF-kappaB and induction of apoptosis.

Authors:  Paolo Onori; Sharon DeMorrow; Eugenio Gaudio; Antonio Franchitto; Romina Mancinelli; Julie Venter; Shelley Kopriva; Yoshiyuki Ueno; Domenico Alvaro; Jennifer Savage; Gianfranco Alpini; Heather Francis
Journal:  Int J Cancer       Date:  2009-08-01       Impact factor: 7.396

10.  Genetic alterations in intrahepatic cholangiocarcinoma as revealed by degenerate oligonucleotide primed PCR-comparative genomic hybridization.

Authors:  Ji-Young Lee; Young-Nyun Park; Kyung-Ok Uhm; Soo-Yeun Park; Sun-Hwa Park
Journal:  J Korean Med Sci       Date:  2004-10       Impact factor: 2.153

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.